{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:36:13Z","timestamp":1792794973943,"version":"4.5.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    This review aimed to summarize the evidence of elevated remnant cholesterol and the risks of atherosclerotic cardiovascular disease (ASCVD) and to search for further guidance in clinical therapy. The lipids-lowering treatments such as statins and ezetimibe targeted on low-density lipoprotein cholesterol (LDL-C) have always been the first-line therapy for ASCVD. However, even after statins or new lipid-lowering drugs lowered LDL-C to recommended concentrations, and with other risk factors well-controlled, such as high blood pressure, the risks of developing ASCVD remained. Remnant cholesterol (RC) referred to the cholesterol contained in all remnant lipoprotein particles, which was the cholesterol in the hydrolyzed very-low-density lipoprotein and intermediate-density lipoprotein in the fasting state, and the cholesterol in the chylomicron remnants in the postprandial state. Evidence from\n                    <jats:italic>in vitro<\/jats:italic>\n                    and animal pathogenic mechanisms studies, epidemiology, and genetic studies all indicated that RC played an important role in predicting the incidence of ASCVD. As a new indicator to reflect atherosclerosis, especially when LDL-C has been controlled to a recommended level, RC was considered as a priority treatment target for people at high risk of ASCVD. The use of statins, fibrates, APOC3 inhibitors, PCSK9 inhibitors, and omega-3 fatty acids to reduce RC levels in the plasma may provide long-term benefits. However, the standardized detection of RC was still controversial, and more studies on appropriate treatments of elevated RC are urgently needed. These positive trials may benefit more patients at high ASCVD risks worldwide in the future.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2022.913869","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:24:57Z","timestamp":1665966297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment"],"prefix":"10.3389","volume":"9","author":[{"given":"Kexin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/eurjpc\/zwab213","article-title":"Editorial for manuscript number EJPC-D-21-01502R1. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019.","volume":"29","author":"Prasad","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/eurjpc\/zwab213","article-title":"Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019.","volume":"11","author":"Safiri","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice.","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European atherosclerosis society task force.","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/2047487319899622","article-title":"Beyond LDL-C levels, does remnant cholesterol estimation matter?","volume":"27","author":"Pirillo","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-5-20","article-title":"Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.","volume":"5","author":"Tenenbaum","year":"2006","journal-title":"Cardiovasc Diabetol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5551\/jat.RV16003","article-title":"Postprandial hyperlipidemia and remnant lipoproteins.","volume":"24","author":"Masuda","year":"2017","journal-title":"J Atheroscler Thromb."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cca.2016.08.012","article-title":"Remnant lipoprotein size distribution profiling via dynamic light scattering analysis.","volume":"462","author":"Chandra","year":"2016","journal-title":"Clin Chim Acta."},{"key":"B10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease.","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease.","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.","volume":"19","author":"Bor\u00e9n","year":"2022","journal-title":"Nat Rev Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/HCO.0000000000000862","article-title":"Triglycerides and cardiovascular disease.","volume":"36","author":"Esan","year":"2021","journal-title":"Curr Opin Cardiol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-1166-5","article-title":"Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.","volume":"18","author":"Dai","year":"2019","journal-title":"Lipids Health Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/MOL.0000000000000680","article-title":"Apolipoprotein C-II: the re-emergence of a forgotten factor.","volume":"31","author":"Wolska","year":"2020","journal-title":"Curr Opin Lipidol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100072","article-title":"Long-lost friend is back in the game.","volume":"62","author":"Kersten","year":"2021","journal-title":"J Lipid Res."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00252","article-title":"Causes and consequences of hypertriglyceridemia.","volume":"11","author":"Packard","year":"2020","journal-title":"Front Endocrinol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans.","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk.","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000190133","article-title":"Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis.","volume":"76","author":"Oda","year":"1997","journal-title":"Nephron."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01076-7","article-title":"The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes.","volume":"19","author":"Cao","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction.","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","article-title":"Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications.","volume":"62","author":"Martin","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.053","article-title":"Remnant cholesterol is just another word for triglycerides when calculating LDL-C using the friedewald formula.","volume":"77","author":"Szili-Torok","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","article-title":"Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population.","volume":"61","author":"Varbo","year":"2015","journal-title":"Clin Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5551\/jat.14.56","article-title":"Increased remnant lipoprotein in patients with coronary artery disease\u2013evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C).","volume":"14","author":"Nakada","year":"2007","journal-title":"J Atheroscler Thromb."},{"key":"B29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jacl.2015.09.006","article-title":"Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: the Very Large Database of Lipids (VLDL-3) study.","volume":"10","author":"Lupton","year":"2016","journal-title":"J Clin Lipidol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease.","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehaa172","article-title":"Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: mendelian randomization in the Copenhagen General Population Study.","volume":"41","author":"Kaltoft","year":"2020","journal-title":"Eur Heart J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk.","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/2047487319887578","article-title":"Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease.","volume":"27","author":"Elshazly","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.740596","article-title":"Association of increased remnant cholesterol and the risk of coronary artery disease: a Retrospective Study.","volume":"8","author":"Kexin","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2022.100335","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American society for preventive cardiology clinical practice statement.","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000624","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J."},{"key":"B38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2012.11.009","article-title":"Remnant cholesterol: \u201cNon-(HDL-C + LDL-C)\u201d as a coronary artery disease risk factor.","volume":"61","author":"McPherson","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B39","article-title":"The role of lipids and lipoproteins in atherosclerosis.","author":"Linton","year":"2000","journal-title":"Endotext."},{"key":"B40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1161\/01.ATV.8.4.421","article-title":"Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall.","volume":"8","author":"Nordestgaard","year":"1988","journal-title":"Arteriosclerosis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease.","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/01.ATV.12.1.6","article-title":"Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants.","volume":"12","author":"Nordestgaard","year":"1992","journal-title":"Arterioscler Thromb."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.1073\/pnas.120184097","article-title":"A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis.","volume":"97","author":"Brown","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5551\/jat.11.200","article-title":"The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor.","volume":"11","author":"Takahashi","year":"2004","journal-title":"J Atheroscler Thromb."},{"key":"B45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans.","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1016\/j.jacc.2020.10.029","article-title":"Remnant cholesterol and atherosclerotic cardiovascular disease risk.","volume":"76","author":"Burnett","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","article-title":"Remnant lipoproteins.","volume":"28","author":"Varbo","year":"2017","journal-title":"Curr Opin Lipidol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1194\/jlr.M700505-JLR200","article-title":"Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.","volume":"50","author":"Wang","year":"2009","journal-title":"J Lipid Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","article-title":"Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.","volume":"114","author":"Kawakami","year":"2006","journal-title":"Circulation."},{"key":"B51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000093221","article-title":"Effects of VLDL and remnant particles on platelets.","volume":"35","author":"Olufadi","year":"2006","journal-title":"Pathophysiol Haemost Thromb."},{"key":"B52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2019.02.019","article-title":"Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography.","volume":"284","author":"Lin","year":"2019","journal-title":"Atherosclerosis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","article-title":"Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European atherosclerosis society and European federation of clinical chemistry and laboratory medicine.","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides.","volume":"52","author":"Johansen","year":"2011","journal-title":"J Lipid Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1093\/hmg\/ddp361","article-title":"A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia.","volume":"18","author":"Hegele","year":"2009","journal-title":"Hum Mol Genet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S1567-5688(11)70033-2","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cca.2018.04.007","article-title":"Remnant-like particles and coronary artery disease in familial hypercholesterolemia.","volume":"482","author":"Tada","year":"2018","journal-title":"Clin Chim Acta."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies.","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat Rev Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.clinthera.2016.02.001","article-title":"Pitavastatin 4 mg provides significantly greater reduction in remnant lipoprotein cholesterol compared with pravastatin 40 mg: results from the short-term phase IV PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia.","volume":"38","author":"Miller","year":"2016","journal-title":"Clin Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2016.01.028","article-title":"Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: the DAIS trial.","volume":"247","author":"Tsunoda","year":"2016","journal-title":"Atherosclerosis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial.","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals.","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res."},{"key":"B69","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes).","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1080\/14656566.2020.1787380","article-title":"Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.","volume":"21","author":"D\u2019Erasmo","year":"2020","journal-title":"Expert Opin Pharmacother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrcardio.2013.117","article-title":"Pharmacotherapies for lipid modification: beyond the statins.","volume":"10","author":"Gotto","year":"2013","journal-title":"Nat Rev Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.913869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:25:04Z","timestamp":1665966304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.913869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":71,"alternative-id":["10.3389\/fcvm.2022.913869"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.913869","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"article-number":"913869"}}